Gelonghui November 2nd 丨Yunnan Baiyao (000538.SZ) was surveyed by specific subjects on October 31, 2023. Regarding “Please tell me about the sales situation of Yunnan Baiyao core series products and other brands of traditional Chinese medicine in the first half of the year”, the company replied that in the first half of 2023, Yunnan Baiyao aerosol contributed more than 900 million yuan in revenue, an increase of 18.20% over the previous year; the revenue of Yunnan Baiyao Cream and Yunnan Baiyao capsules continued to grow. In terms of other brands of traditional Chinese medicine products, seizing market expansion opportunities, the business and OTC sectors have expanded and increased the scope of multiple products through medium output and product-driven methods. The revenue of a single product of Futilan anti-inflammatory tablets for colds was over 100 million, up 80% year on year, and revenue from common wind stop capsules increased 27% year over year; Agastache Zhengqi Water, a proprietary Chinese medicine that removes heat and moisture, increased sharply by more than 260% year on year, ranking among the company's top ten product sales in the first half of the year.
Yunnan Baiyao (000538.SZ): In the first half of the year, Yunnan Baiyao aerosol contributed more than 900 million yuan in revenue, an increase of 18.20% over the previous year
Gelonghui Finance · 11/02/2023 19:12
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.